Companies Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics CEO salary & total pay, FY2025: $4.7M
Aldeyra Therapeutics (ALDX) CEO salary, fiscal 2025: Todd Brady was paid a salary of $700,000 and $4,704,179 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Aldeyra Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Todd Brady's complete compensation dossier
A PDF and a CSV sent to your email: Todd Brady's pay in every fiscal year Aldeyra Therapeutics, Inc. reported it, line by line, with Todd Brady's equity grants and Aldeyra Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $3,684,651FY2023
- $3,931,645FY2024
- $4,704,179FY2025
CEO total pay was $4,704,179 in fiscal 2025, up from $3,931,645 in fiscal 2024.
FY2025: salary $700,000 · bonus $0 · stock awards $0 · option awards $3,801,379
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Todd Brady | $700,000 | $0 | $0 | $3,801,379 | $189,000 | $0 | $14,000 | $4,704,179 |
| President and Chief Executive Officer | ||||||||
| Stephen Machatha | 400,000 | — | — | 950,342 | — | — | 101,800 | 1,452,142 |
| Chief Development Officer | ||||||||
| Michael Alfieri | 0 | 0 | 0 | 0 | 0 | 0 | 243,994 | 245,963 |
| Principal Financial Officer and Principal Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Todd Brady | $4,704,179 | $3,931,645 | $3,684,651 | ↑ +772,534 |
| Stephen Machatha | 1,452,142 | 1,688,381 | 1,593,108 | ↓ −236,239 |
| Michael Alfieri | 245,963 | 111,650 | — | ↑ +134,313 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The executive compensation program is designed to ensure consistency with short-term and long-term goals, attract and retain talent, and align the interests of named executive officers with stockholders by providing compensation based on the achievement of pre-established corporate financial goals. The program emphasizes a pay-for-performance philosophy where variable compensation and long-term equity incentives represent over 75% of target direct compensation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Todd Brady | OPTION | 2025-03-04 | — | — | 809,710 | — | $3,801,379 |
| Stephen Machatha | OPTION | 2025-03-04 | — | — | 202,427 | — | 950,342 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Todd Brady | $0 | $0 | $3,801,379 | 0.0% |
| Stephen Machatha | 0 | 0 | 950,342 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Stephen Machatha | Option | 244,791 | 5,209 | 4.52 | — |
| Stephen Machatha | RSU | — | 16,099 | — | 83,393 |
| Stephen Machatha | RSU | — | 46,402 | — | 240,362 |
| Stephen Machatha | Option | 160,604 | 59,654 | 6.76 | — |
| Stephen Machatha | Option | 194,278 | 211,172 | 3.62 | — |
| Stephen Machatha | Option | 46,389 | 156,038 | 6.17 | — |
| Stephen Machatha | Option | 35,000 | — | 4.6 | — |
| Stephen Machatha | Option | 26,200 | — | 5.25 | — |
| Stephen Machatha | Option | 45,573 | — | 8.35 | — |
| Stephen Machatha | Option | 63,000 | — | 8.05 | — |
| Stephen Machatha | Option | 135,560 | — | 3.78 | — |
| Stephen Machatha | Option | 116,201 | — | 11.71 | — |
| Todd Brady | Option | 244,791 | 5,209 | 4.52 | — |
| Todd Brady | RSU | — | 62,500 | — | 323,750 |
| Todd Brady | Option | 182,291 | 67,709 | 6.76 | — |
| Todd Brady | RSU | — | 119,375 | — | 618,363 |
| Todd Brady | Option | 518,075 | 563,126 | 3.62 | — |
| Todd Brady | Option | 185,558 | 624,152 | 6.17 | — |
| Todd Brady | Option | 250,000 | — | 4.59 | — |
| Todd Brady | Option | 250,000 | — | 5.1 | — |
| Todd Brady | Option | 217,293 | — | 8.6 | — |
| Todd Brady | Option | 250,000 | — | 8.05 | — |
| Todd Brady | Option | 250,000 | — | 3.78 | — |
| Todd Brady | Option | 250,000 | — | 11.71 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Richard H. Douglas, Ph.DIndependent · Board Chair · Nominating/Corporate Governance · Not standing for re-election | $61,750 | — | $163,466 | — | — | $225,216 |
| Martin J. Joyce, M.B.AIndependent · Audit (Chair) · Nominating/Corporate Governance · Not standing for re-election | 49,250 | — | 148,469 | — | — | 197,719 |
| Gary M. Phillips, M.DIndependent · Audit · Compensation (Chair) · Not standing for re-election | 48,750 | — | 147,468 | — | — | 196,218 |
| Ben R. Bronstein, M.DIndependent · Audit · Nominating/Corporate Governance (Chair) · Not standing for re-election | 47,250 | — | 145,469 | — | — | 192,719 |
| Neal S. Walker, D.OIndependent · Compensation · Not standing for re-election | 42,500 | — | 134,972 | — | — | 177,472 |
| Nancy B. Miller-RichIndependent · Compensation · Not standing for re-election | 42,500 | — | 134,972 | — | — | 177,472 |
| William D. ClarkIndependent · Not standing for re-election | 28,222 | — | 134,237 | — | — | 162,459 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $130,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 5,000 / 3,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $320,222 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $320,222 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Aldeyra Therapeutics as a peer
Companies that benchmark against ALDX
2 companies name ALDX as a compensation peer
- Adverum Biotechnologies, Inc.ADVMFY2024
- Opus Genetics, Inc.IRDFY2025
Each company listed discloses ALDX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALDX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Aldeyra Therapeutics, Inc. | 2025 | Todd Brady | $700,000 | $0 | $3,801,379 | $189,000 | $4,704,179 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 19,477,504 | 4,543,221 | 87,138 | 80.79% | Passed |
| 2025 | 2025-06-10 | 18,847,620 | 7,919,279 | 181,465 | 69.94% | Passed |
| 2024 | 2024-06-04 | 31,493,319 | 2,862,040 | 126,606 | 91.33% | Passed |
| 2023 | 2023-06-30 | 27,710,251 | 646,060 | 57,323 | 97.52% | Passed |
| 2022 | 2022-06-07 | 23,243,909 | 3,179,900 | 65,334 | 87.75% | Passed |
| 2021 | 2021-06-08 | 20,666,431 | 5,734,541 | 126,458 | 77.91% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 80.79%a |
| 2025 | 2025-06-10 | 69.94%b |
| 2024 | 2024-06-04 | 91.33%c |
a. Approved under the standard stated in the filing — “Required Vote and Recommendation of the Board of Directors for Proposal 3 A " FOR " vote from the holders of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting is required to approve, on a non-binding, advisory basis, the compensation of our named executive officers. || Abstentions: Abstentions and broker non-votes will have the same effect as a vote "Against" this matter.”.
b. Approved under the standard stated in the filing — “Required Vote and Recommendation of the Board of Directors for Proposal 3 A " FOR " vote from the holders of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting is required to approve, on a non-binding, advisory basis, the compensation of our named executive officers. || Abstentions: Abstentions and broker non-votes will have the same effect as a vote "Against" this matter.”.
c. Approved under the standard stated in the filing — “Required Vote and Recommendation of the Board of Directors for Proposal 3 A " FOR " vote from the holders of a majority of the shares of common stock present in person or represented by proxy at the Annual Meeting is required to approve, on a non-binding, advisory basis, the compensation of our named executive officers. || Abstentions: Abstentions and broker non-votes will have the same effect as a vote "Against" this matter.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Todd Brady | Director | 2026-06-03 | A | 250,000 | $2 | $418,450 | Common | Form 4 ↗ |
| William D. Clark | Director | 2026-06-09 | A | 2,323 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William D. Clark | Director | 2026-06-09 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy B. Miller-Rich | Director | 2026-06-09 | A | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy B. Miller-Rich | Director | 2026-06-09 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene M. Deptula-Hicks | Director | 2026-06-09 | A | 9,756 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Darlene M. Deptula-Hicks | Director | 2026-06-09 | A | 84,557 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Bronstein | Director | 2026-06-09 | A | 4,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Bronstein | Director | 2026-06-09 | A | 5,309 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ben Bronstein | Director | 2026-06-09 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neal Walker | Director | 2026-06-09 | A | 3,318 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neal Walker | Director | 2026-06-09 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary M. Phillips | Director | 2026-06-09 | A | 4,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary M. Phillips | Director | 2026-06-09 | A | 6,636 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gary M. Phillips | Director | 2026-06-09 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-09 | A | 2,323 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-09 | A | 19,909 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-09 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Alfieri | Principal Financial Officer | 2026-11-11 | A | 10,000 | 1 | 6,500 | Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-11-11 | A | 200,000 | 1 | 128,900 | Common | Form 4 ↗ |
| Darlene M. Deptula-Hicks | Director | 2026-11-12 | A | 7,500 | 1 | 4,875 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (40 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Todd Brady. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 28. As printed: 4,704,179. View filing ↗
- Section 01, Stephen Machatha. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 28. As printed: 1,452,142. View filing ↗
- Section 01, Michael Alfieri. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 28. As printed: 245,963. View filing ↗
- Section 03, Todd Brady OPTION. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Stephen Machatha OPTION. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Richard H. Douglas, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 225,216. View filing ↗
- Section 08, Martin J. Joyce, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 197,719. View filing ↗
- Section 08, Gary M. Phillips, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 196,218. View filing ↗
- Section 08, Ben R. Bronstein, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 192,719. View filing ↗
- Section 08, Neal S. Walker, D.O. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 177,472. View filing ↗
- Section 08, Nancy B. Miller-Rich. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 177,472. View filing ↗
- Section 08, William D. Clark. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 162,459. View filing ↗
- Section 02, Todd Brady 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William D. Clark 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William D. Clark 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy B. Miller-Rich 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy B. Miller-Rich 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene M. Deptula-Hicks 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene M. Deptula-Hicks 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Bronstein 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Bronstein 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ben Bronstein 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Neal Walker 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Neal Walker 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary M. Phillips 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary M. Phillips 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary M. Phillips 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Douglas 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Douglas 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Douglas 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Alfieri 2026-11-11. Form 4, filed 2026-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard Douglas 2026-11-11. Form 4, filed 2026-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Darlene M. Deptula-Hicks 2026-11-12. Form 4, filed 2026-11-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 80.79% (votes for as printed: 19,477,504). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-11. Item 5.07 · say-on-pay result. As reported: 69.94% (votes for as printed: 18,847,620). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 91.33% (votes for as printed: 31,493,319). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 320,222 + equity 0 + all other 0 = 320,222, summed across the director compensation table rows.
- Aldeyra Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Aldeyra Therapeutics, Inc.'s own proxy. As printed: 4,704,179. View filing ↗